Discover the latest insight in these articles and events featuring inThought analysts and executives.
Elevate Medical Affairs Podcast: Innovative Technologies for Smarter Pharma-Healthcare Interactions
January 9, 2023
Listen to an episode of Elevate Medical Affairs Podcast featuring Ben Weintraub, PhD, President of inThought, who was awarded Top Idea of the Year Silver Medalist of the Medical Affairs Olympics Competition.
Pipeline Report 2023: Patient experience takes center stage
December 7, 2022
The past two years were all about COVID-19 vaccines and therapeutics. Now, imminent approvals in oncology, hematology and autoimmune disorders are set to enhance patient convenience.
inThought featured on CNBC Business Channel’s Inside the Blueprint
July 1, 2022
inThought has been selected to be featured on CNBC Business Channel’s Inside the Blueprint. Our company was selected as an industry leader in business consulting services on the local New York City edition of the show.
Pipeline Report 2022: Several Blockbuster Drugs are Poised to go Bigger and Broader
November 2, 2021
Therapies in the oncology, neurology and autoimmune disease pipelines could soon pose challenges to existing standards of care.
BI Analyst Briefing: What’s New in Skin and Auto-Immune Disorders?
November 2, 2021
Please join us to review recent and upcoming clinical and regulatory developments in skin and auto-immune disease. Bloomberg Intelligence analyst Michael Shah, and Senior Principal of inThought Research Amanda Weyerbacher, PhD, will be joined by dermatologist Steven R. Feldman, MD, PhD and rheumatologist Christopher Ritchlin MD, MPH, for a discussion around prescribing trends, the competitive landscape and key mechanisms and drugs of interest, including the JAK class, Bimzelx, Dupixent and lebrikizumab.
BI Analyst Briefing: ASCO Highlights Review
June 9, 2021
Please join us for a review of key data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Bloomberg Intelligence analysts Marc Engelsgjerd, MD, and Sam Fazeli, PhD, and inThought Research analyst Matt Presby, PhD, will be joined by expert speakers Patrick Forde, MBBCh, and Ravi Vij, MD, for a discussion of ASCO presentations of interest, including emerging data from checkpoint inhibitors, cell therapies, and targeted small molecules.
The MM&M Podcast 2.5.2021: inThought Research’s Dr. Leon Henderson-MacLennan
February 5, 2021
Is biopharma slowly cracking the code on Alzheimer’s disease? Leon Henderson-MacLennan, M.D., of inThought Research, joins Marc Iskowitz, editor-at-large for MM+M, to explain why January was a pivotal month in neuroscience and why marketers should watch this space.
Pipeline Report 2021: Promising Drugs Tick Along Across a Range of Conditions
December 8, 2020
As drug developers swim hard and fast to neutralize COVID-19 with vaccines and therapeutics, they are also working to get other important drugs approved amid looming threats of halts and delays. 2021 is looking to be a big year for the pharma pipeline.
Biogen’s Touted Alzheimer’s Drug Receives Thumbs-Down from FDA Advisory Panel
November 9, 2020
Biogen’s quest to get a long-awaited new Alzheimer’s drug to market took yet another twist on Friday afternoon as the FDA advisory committee (AdCom) issued an unfavorable vote on recommending the drug for approval.
Spinal Muscular Atrophy Expert Call
September 18, 2020
Bloomberg Intelligence and inThought host a call with Spinal Muscular Atrophy experts for an in-depth review of the spinal muscular atrophy (SMA) treatment landscape, which now includes approved drugs from Biogen, Novartis and Roche.
inDemic Announces New Research Tool for the COVID-19 Pandemic
September 3, 2020
inDemic announces the launch of its COVID-19 knowledge management system. inDemic’s initial focus is on COVID-19 therapies and vaccines. The site provides in-depth news and analysis of therapies that are being tested to treat COVID-19.
COVID-19 Therapeutics Expert Call
April 20, 2020
Bloomberg Intelligence and inThought will host a call with immunology experts to discuss development of a Covid-19 therapy and how best to interpret clinical data once they begin to emerge.
COVID-19 Vaccines Expert Call
April 2, 2020
Bloomberg Intelligence healthcare analysts and inThought Research experts share their views on the prospects for developing a vaccine against the novel coronavirus.
Pipeline Report 2020: Drugs Rising from R&D Purgatory
December 5, 2019
inThought Research president Ben Weintraub discusses drugs re-emerging from “R&D purgatory” with MM&M.
The MM&M Podcast 5.29.2019: inThought Research’s Michelle Rivera
May 29, 2019
inThought Research analyst Michelle Rivera speaks with MM&M about the pathophysiology of the disease spinal muscular atrophy (SMA), the SMA drug pipeline, and how payers may react expensive drugs.
Novartis gene therapy gets green light, and a price tag of $2.1 million
May 24, 2019
The FDA cleared Novartis gene therapy Zolgensma in infants with the genetic disease SMA. Its price tag, $2.1 million, can be paid out over five years and comes with a partial performance-based rebate.
The 2019 pipeline report: Changing the treatment paradigm
December 4, 2018
Are today’s developmental drugs tomorrow’s blockbusters? MM&M surveys what’s ahead for top candidates in six therapeutic categories.
Promising rare conditions treatments could upend the market hierarchy
October 4, 2018
With less than 14% of Phase I to III drug candidates winning FDA approval, unforeseen roadblocks can derail even the most promising clinical research programs.
Orphan drugs leveraging new tech promise to cure disease
August 2, 2018
Two late-stage orphan drugs are upping the ante with their promise to cure disease.
Did the market overreact to Biogen’s Alzheimer’s data?
July 10, 2018
Biogen’s recently soaring stock price can be attributed to investor optimism in one of the most stubborn areas of drug development.
The 2018 pipeline report: Aspiring assets to keep an eye on
December 4, 2017
The most promising products in pharma’s pipeline compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch.
The immuno-oncology market prepares for the inevitable question: ‘What’s next?’
June 1, 2017
Questions remain about the effectiveness—and cost-effectiveness—of drugs like Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo, in combination or alone.
